MINUTES OF THE MEETING FOR REDRESSAL OF GRIEVANCE COMMITTEE

A meeting of the Grievance Committee constituted vide letter No. /57448-54 /MH., Dated 14-09-2020, Grievance meeting held on 28.10.2020 at 10:00 a.m., in the & 21-07-2020 for the year 2020-21.

1	For Code No A035 PROCUREMENT OF ANTI CANCER DRUGS M/S -Synchro Pharmaceuticals submitted a grievance vide their letter No. Nil dated 15- 09-2020 bearing Diary No.8325 Dated 19.10.2020. He stated that their company supply of medicine against the following non-responsive bids we may kindly be informed that reason of being non-responsive. T.E. No. 19 H.F. No. 439 Inj.Ondansetron. As we are working with your esteem hospital from the last so many years and always try to meets the criteria and standard.	Non-responsive for quoted item due to not obtaining qualifying marks in part B.	Mr Suleman Toquer attended the meeting on behalf of M/S Synchro Pharmaceuticals .He explained the matter and presented documents. the committee evaluated the bid and documents in accordance to evaluation criteria. However the bid failed to attain the qualifying percentage. After due deliberation, the committee unanimously decided to unhold the decision
2	For Code No A035 PROCUREMENT OF ANTI CANCER DRUGS M/S - Pharmasol PVT Ltd submitted a grievance vide their letter No. Nil dated Nil bearing Diary No.8370 Dated 17.10.2020. He is stated that Pharmasol has started its production in December 2017 as the age of the company is less therefore experience is less than two years. Such record will build up with the passage of time.	Non –Responsive for all quoted items due to having product experience less than two years.	decided to uphold the decision of T.E.C. Hence the grievance is rejected. Mr. Zahid Latif (Business Development manager) attended the meeting on behalf of M/S Pharmasol pvt Ltd .He explained his grievance. The committee evaluated the matter. However the bid failed to comply the compulsory parameter (minimum 2 years

d. W

Su

Jm/

	He is requested for grace period for qualification in medicine tender 2020-21.		After due deliberation, the committee unanimously decided to uphold the decision of T.E.C. Hence the grievance is rejected.
3	For Code No A035 PROCUREMENT OF ANTI CANCER DRUGS M/S – Oncolink Pharm distributors submitted a grievance vide their letter No. Nil dated October 15,2020 bearing Diary No.1415 Dated 16.10.2020. He is stated that he is authorized Distributor of AJM, Pharmdic, Helix and Macter. In technical evaluation he is declared non-responsive for the following items. Tender enquiry NO. 1,4,5,9,10,11,12,14,15,21,23,24,27, In this regard we would like to your kind notice that we had provided all the required documents to get at least passing marks for all the above-Mentioned items as per evaluation criteria. Also please note that it has been 3 years we are supplying Macdronic and letara while 2 years of Robol ,Sedol ,Oxol to Mayo Hospital but unfortunately these items are disqualified this year.	Non-Responsive for quoted items at T.E. # 1/255,4/246, 5/247,9/252, 10/252, 11/253, 12/277,14/251, 21/265, 23/271,24/289, 27/285 due to not obtaining qualifying marks in Part B.	Mr Ashraf Zubairi attended the meeting on behalf of M/S Onolink Pharma. He presented his arguments over the matter. The committee evaluated the bid and documents in accordance to evaluation criteria in detail However the certain items failed to attain the qualifying percentage. After due deliberation, the committee unanimously decided to uphold the decision of T.E.C. Hence the grievance is rejected.
4	For Code No A016 PROCUREMENT OF INJ. PROPOFAL. M/S – Allied distributors submitted a grievance vide their letter No. Nil dated 13-10-2020 bearing Diary No.8369 Dated 17.10.2020. He is stated that the said items Pofol (Propofol) is an imported product from M/s-Dong	Bid is non-Responsive against quoted item due to failure in part C (Not approved by end user)	

Jm/

gr

Kook Pharmaceutical CO Ltd, South Korea & is purchased in a lot of Public/Private institution in Punjab .

In case of Pofol it is not that manufacturing technology is taken from some other company, the fact of the matter is that Dong Kook itself has successfully synthesized propofol and developed a propofal based emulsion of use in injection.

Human clinical studies were also performed and one of the studies based on double blind method was performed at seoul national university hospital anesthesia department.

It was concluded that Paofol (Produced by Dong Kook Pharm co Ltd) when compared with Brand D shoed no difference in efficacy . In terms of safety the frequency of said effects was about the same for both, and these side effects cleared up without any difficulty. A Comparative clinical study of Pofol & Propofal Lipuro was also conduct in LRH Peshwar and pofol was found more effective.

We has also provided the samples in the current tender so that the samples may be used to evaluate the efficacy of product. Whatever the efficacy you found may be given to our firm so that we may discuss it with our principal /Ms/Dong Kook , Seoul Korea.

committee evaluated the matter. End user disapproved the product and did not recommend it in Part C.

After due deliberation, the committee unanimously decided to **uphold** the decision of T.E.C.

Hence the grievance is rejected.

STOD O

Dr. Muhammad Iqbal Additional Medical Superintendent **Member** Grievance Committee

Amaz Afral

Prof. Dr. Ameer Afzal Professor Of North Surgery Chairman Grievance Committee

Saadia Arshad Rana

Member Grievance Committee